XAPIEN: The Knowledge to Lead.

Overview

Knowledge and technology can only provide economic impact in drug discovery if they are accompanied with strategic thinking. Envisioning these assets in terms of their ability to deliver superior medicines, with increased market potential, at lower cost and in reduced timeframes remains an industry wide challenge. XAPIEN's founding team has embraced these issues to propose a new path forward. Driven by the prerequisites of in silico-based discovery, XAPIEN intends to build its business firmly on the value derived from a novel strategy termed 'Chemosysteomics'.

Goals

XAPIENs in silico driven discovery platform will enable us to:

• Secure maximum patent coverage for existing and newly discovered medicines.
• Expand the present view of "one drug, single target, lone disease", by developing strategies for combinatorial therapeutic intervention.
• Diminish the appalling rates of attrition by prioritizing safer and higher efficacy drugs.

The platform holds not only the key to addressing the 'innovation deficit', but also promises to herald a new generation of drug discovery based more on the tenets of engineering than those of chance.